JSR Life Sciences has entered a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited, enabling Crown to focus on oncology advancements under Adicon's support.

Information on the Target

JSR Life Sciences LLC has entered into a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited. Crown Bioscience is a leading global contract research organization (CRO) specializing in oncology and immuno-oncology drug discovery. The company offers a range of translational oncology services, including an extensive portfolio of patient-derived xenograft (PDX) models, tumor organoid platforms, immuno-oncology assays, and advanced bioinformatics solutions. By transitioning to Adicon, Crown Bioscience aims to enhance its capabilities and accelerate growth in precision medicine and drug discovery within the oncology sector.

The Global Biospecimens business of Crown Bioscience, based in Hamburg, Germany, along with facilities in Frederick, Maryland, will continue to operate under JSR Life Sciences. This integration allows the Biospecimens team to leverage JSR's global resources and innovation ecosystem, focusing on ethical sourcing, custom procurement, and advanced sample processing and storage capabilities.

Industry Overview in Target’s Specific Country

The oncology industry in China is rapidly evolving, driven by advancements in biotechnology and increasing funding for research and development. The demand for innovative cancer treatments and robust diagnostic solutions has led to a surge